RxDoctor Payments Data

Ali Tabatabai, MD

Internal Medicine · Laguna Hills, CANPI 1528098423

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 32 payments — averaging $39.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$286
  • Novo Nordisk$242
  • Abbott$192
  • Novartis$181
  • Amgen$121
  • Biogen$120
  • plus $127 from 3 others

What the payments were for

  • Food & beverage$1,268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,268 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,334,212
Medicare patients
717
Services billed
12,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide12$110,351
EliquisApixaban163$82,433
XareltoRivaroxaban92$63,531
JardianceEmpagliflozin58$51,916
OzempicSemaglutide49$44,125
LinzessLinaclotide31$35,857
JanuviaSitagliptin Phosphate33$24,294
TrulicityDulaglutide15$18,197
VascepaIcosapent Ethyl38$17,084
Breo ElliptaFluticasone/Vilanterol21$14,744
FarxigaDapagliflozin Propanediol21$13,415
EdarbiAzilsartan Medoxomil14$9,919
Emgality PenGalcanezumab-Gnlm13$9,032
TradjentaLinagliptin13$9,014
Tresiba Flextouch U-100Insulin Degludec16$7,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$286$63,53192 claims
Novo NordiskOzempic$242$44,12549 claims
Lilly USA, LLCTrulicity$91$18,19715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →